Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in PTPN2.

Funding – BBSRC funded 4-year studentship, providing tuition fees, training/research costs and an annual stipend at the UKRI rate, currently £19,237 Start Date – September 2025 Applicants are expected ...

10 μg of protein was used to detect the expression levels of FGFR2-initiated downstream signaling molecules by SDS-PAGE, electro-transfer and immunoblotting with specific antibodies. The following ...

Huang, B.T., Li, K.F., Wu, X.S., Zhang, F.Y. and Li, Y.P. (2025) Application and Research Advancement of Antibody-Conjugated Drugs in Non-Small Cell Lung Cancer. Journal of Biosciences and Medicines, ...

Signalling through the ERBB/HER receptors ... that is aimed at increasing network robustness. The primordial receptor tyrosine kinase (RTK) might have been formed through a gene-fusion event ...

Furthermore, it was shown that LPA induces a transient increase in MLC phosphorylation and that the effect of LPA on barrier function was mediated by Rho kinase. Rather high concentrations of LPA were ...